Stock Market News
Premaitha's IONA test given green light by Brazilian regulator
International molecular diagnostics group Premaitha Health announced on Monday that its IONA test product has been approved by Brazil's regulatory authority, Agência Nacional de Vigilância Sanitária (ANVISA), for sale as an in vitro diagnostic test.
The AIM-traded firm had announced in September last year that the IONA test had been approved by ANVISA for Brazilian 'Good Manufacturing Practice' (B-GMP), which was required to enable Premaitha to proceed with its official application to register the product with ANVISA, which was completed ahead of expectations in under three months.
It said it was now seeking commercial partners in Brazil to bring non-invasive prenatal testing product to pregnant women and their clinicians in the country.
Premaitha said its IONA test estimated the risk of a fetus being affected with Down's syndrome or other genetic conditions.
The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using what the company described as "next generation" DNA sequencing technology. It said the test is "highly accurate", and significantly reduced the number of women who were unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions.
"Commercialising the IONA test in this significant South American market is another key step in Premaitha's diversification and de-risking strategy," said CEO Dr Stephen Little.
"Whilst the territory will not be immediately revenue generating, with over three million births per annum, we anticipate Brazil will become a major market for Premaitha and that it will in due course provide a springboard to other South and Central America regions.
"Furthermore, the rapid regulatory approval process is another endorsement of the quality management system Premaitha has built from the outset that is of a calibre suitable for multiple regulatory regimes of the highest standards globally."
The AIM-traded firm had announced in September last year that the IONA test had been approved by ANVISA for Brazilian 'Good Manufacturing Practice' (B-GMP), which was required to enable Premaitha to proceed with its official application to register the product with ANVISA, which was completed ahead of expectations in under three months.
It said it was now seeking commercial partners in Brazil to bring non-invasive prenatal testing product to pregnant women and their clinicians in the country.
Premaitha said its IONA test estimated the risk of a fetus being affected with Down's syndrome or other genetic conditions.
The test is performed on a maternal blood sample, containing traces of fetal DNA, which is then analysed using what the company described as "next generation" DNA sequencing technology. It said the test is "highly accurate", and significantly reduced the number of women who were unnecessarily subjected to risky, invasive follow up procedures to diagnose Down's syndrome and other genetic conditions.
"Commercialising the IONA test in this significant South American market is another key step in Premaitha's diversification and de-risking strategy," said CEO Dr Stephen Little.
"Whilst the territory will not be immediately revenue generating, with over three million births per annum, we anticipate Brazil will become a major market for Premaitha and that it will in due course provide a springboard to other South and Central America regions.
"Furthermore, the rapid regulatory approval process is another endorsement of the quality management system Premaitha has built from the outset that is of a calibre suitable for multiple regulatory regimes of the highest standards globally."
Related share prices |
---|
Premaitha Health (NIPT) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price